Close Menu

NEW YORK (GenomeWeb) – Enzo Biochem today announced that it has received a favorable claim construction ruling that will govern 10 ongoing patent suits the firm has brought to defend three US patents.

The firm said the US District Court for the District of Delaware has adopted Enzo's proposed constructions for the majority of the disputed claim terms and rejected the defendants' argument that Enzo's US Patent No. 6,992,180 for phosphate-moiety labeled oligonucleotide reagents is invalid for indefiniteness.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports on the struggle to meet the demand for rapid COVID-19 testing.

The Newsroom reports New Zealand is using genomics to trace the origins of its new coronavirus outbreak.

In Nature this week: researchers in Canada sequence the genome of the black mustard plant Brassica nigra, and more.

According to Bloomberg, Moderna has a $1.5 billion vaccine deal with the US to provide 100 million doses.